FEB 23·GlobeNewswireHigh
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
Fortress Biotech's majority-owned subsidiary, Cyprium Therapeutics, has announced an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million. This PRV was issued following the FDA approval of ZYCUBO for Menkes disease, with Sentynl Therapeutics having assumed responsibility for its development and commercialization. Cyprium is also eligible for royalties and milestones from Sentynl, and will pay 20% of the PRV proceeds to the NIH.